|
New Perspective on the Action Mechanism of Doxorubicin in Breast Cancer- Overexpressions of miR-874-3p and miR-337-3p and Downregulation of STAT3 Gene
|
Siroos Tarighi    , Maryam Montazeri * , Fatemeh Rohollah |
|
|
|
Abstract: (1029 Views) |
Background: Breast cancer is one of the common malignancies in women, for which doxorubicin (DOX) is widely used in its chemotherapy. Recently, it has been found that DOX affects the expression profile of oncogene genes and miRNAs. In this study, the impacts of DOX on the expressions of the STAT3 gene, miR-874-3p, and miR-337-3p were studied in the MCF-7 breast cancer cell line.
Methods: After exposure of MCF-7 cells with DOX, the MTT method was applied for evaluating the cell viability. Apoptosis and necrosis percentages were measured using flow cytometry. Also, the levels of ROS and NF-κB were measured in DOX-treated cells. Then, exosomes secreted from these cells were prepared. The shape of exosomes was studied by SEM. Finally, the expression of bax, bcl-2, p53, casp3, STAT3 gene, and miR-874-3p and miR-337-3p in MCF-7 cells as well as exosomes were evaluated using the RT-PCR technique. Data analysis was done by T-test in GraphPad Prism8 software.
Results: The exposure of MCF-7 cells to doxorubicin led to a concentration-dependent decrease in cell viability and increases in apoptosis and necrosis. ROS and NF-κB activity were increased in DOX-treated cells. In DOX-treated cells, decreased expressions of bcl-2 and STAT3 genes and overexpression of bax, p53, casp3, miR-874-3p, and miR-337-3p were observed compared to untreated control cells.
Conclusion: One of the mechanisms of the anti-breast cancer effects of DOX is the induction of changes in the expression of oncogenic genes, mediating by downregulating of STAT3 gene and overexpressing miR-874-3p and miR-337-3p. More studies are needed in this field. |
|
|
| Keywords: Breast cancer, Gene, miRNA, Doxorubicin |
|
|
Full-Text [PDF 1235 kb]
(193 Downloads)
|
Type of Study: Research |
Subject:
Gene expression
Received: 2023/07/4 | Accepted: 2023/05/20 | Published: 2023/05/20
|
|
|
|
|
|
|
| References |
1. Banegas MP, Bird Y, Moraros J, King S, Prapsiri S, Thompson B. Breast cancer knowledge, attitudes, and early detection practices in United States-Mexico border Latinas. J Womens Health (Larchmt). 2012;21(1):101-7. [ DOI:10.1089/jwh.2010.2638] [ PMID] [ ] 2. Shahbazi S, Alavi S, Majidzadeh-A K, GhaffarPour M, Soleimani A, Mahdian R. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Medical Oncology. 2013;30(1):393. [ DOI:10.1007/s12032-012-0393-7] [ PMID] 3. Venkitaraman AR. How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility? DNA Repair. 2019;81:102668. [ DOI:10.1016/j.dnarep.2019.102668] [ PMID] [ ] 4. Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E. Breast cancer risk factors. Menopause Review/Przegląd Menopauzalny. 2015;14(3):196-202. [ DOI:10.5114/pm.2015.54346] [ PMID] [ ] 5. Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. New England Journal of Medicine. 6. 1996;334(21):1356-61. 7. van der Zanden SY, Qiao X, Neefjes J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. The FEBS Journal. 2021;288(21):6095-111. [ DOI:10.1111/febs.15583] [ PMID] [ ] 8. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440-6. [ DOI:10.1097/FPC.0b013e32833ffb56] [ PMID] [ ] 9. Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. British Journal of Cancer. 2015;113(3):365-71. [ DOI:10.1038/bjc.2015.233] [ PMID] [ ] 10. Rosmorduc O, Desbois-Mouthon C. Targeting STAT3 in hepatocellular carcinoma: Sorafenib again…. Journal of hepatology. 2011;55(5):957-9. [ DOI:10.1016/j.jhep.2011.06.005] [ PMID] 11. Wong AL, Soo RA, Tan DS, Lee SC, Lim JS, Marban PC, et al. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Annals of Oncology. 2015;26(5):998-1005. [ DOI:10.1093/annonc/mdv026] [ PMID] 12. Chen Y, Wang J, Wang X, Liu X, Li H, Lv Q, et al. STAT3, a poor survival predicator, is associated with lymph node metastasis from breast cancer. Journal of breast cancer. 2013;16(1):40-9. [ DOI:10.4048/jbc.2013.16.1.40] [ PMID] [ ] 13. Niemand C, Nimmesgern A, Haan S, Fischer P, Schaper F, Rossaint R, et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. The journal of immunology. 2003;170(6):3263-72. [ DOI:10.4049/jimmunol.170.6.3263] [ PMID] 14. Wu G, Zhou H, Li D, Zhi Y, Liu Y, Li J, et al. LncRNA DANCR upregulation induced by TUFT1 promotes malignant progression in triple negative breast cancer via miR-874-3p-SOX2 axis. Experimental Cell Research. 2020;396(2):112331. [ DOI:10.1016/j.yexcr.2020.112331] [ PMID] 15. Wang Y, Chen H, Wei X. Circ_0007142 downregulates miR-874-3p-mediated GDPD5 on colorectal cancer cells. European Journal of Clinical Investigation. 2021;51(7):e13541. [ DOI:10.1111/eci.13541] [ PMID] 16. Leong KW, Cheng CW, Wong CM, Ng IO, Kwong YL, Tse E. miR-874-3p is down-regulated in hepatocellular carcinoma and negatively regulates PIN1 expression. Oncotarget. 2017;8(7):11343-55. [ DOI:10.18632/oncotarget.14526] [ PMID] [ ] 17. Luo S-D, Tsai H-T, Hwang C-F, Chiu TJ, Li SH, Hsu Y-L, et al. Aberrant miR-874-3p/leptin/EGFR/c-Myc signaling contributes to nasopharyngeal carcinoma pathogenesis. Journal of Experimental & Clinical Cancer Research. 2022;41(1):1-20. [ DOI:10.1186/s13046-022-02415-0] [ PMID] [ ] 18. Que K, Tong Y, Que G, Li L, Lin H, Huang S, et al. Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway. Oncology reports. 2017;38(6):3376-86. [ DOI:10.3892/or.2017.6041] [ PMID] [ ] 19. Liu W-G, Zhuo L, Lu Y, Wang L, Ji Y-X, Guo Q. miR-874-3p inhibits cell migration through targeting RGS4 in osteosarcoma. The Journal of Gene Medicine. 2020;22(9):e3213. [ DOI:10.1002/jgm.3213] [ PMID] 20. Zhang Z, Zhang L, Wang B, Wei R, Wang Y, Wan J, et al. MiR-337-3p suppresses proliferation of epithelial ovarian 21. cancer by targeting PIK3CA and PIK3CB. Cancer Letters. 2020;469:54-67. [ DOI:10.1016/j.canlet.2019.10.021] [ PMID] 22. Meng Q-h, Li Y, Kong C, Gao X-m, Jiang X-j. Circ_0000388 exerts oncogenic function in cervical cancer cells by regulating miR-337-3p/TCF12 axis. Cancer Biotherapy & Radiopharmaceuticals. 2021;36(1):58-69. [ DOI:10.1089/cbr.2019.3159] [ PMID] 23. Wang Z, Wang J, Yang Y, Hao B, Wang R, Li Y, et al. Loss of has-miR-337-3p expression is associated with lymph node metastasis of human gastric cancer. Journal of Experimental & Clinical Cancer Research. 2013;32(1):76. [ DOI:10.1186/1756-9966-32-76] [ PMID] [ ] 24. Wang Z, Yao L, Li Y, Hao B, Wang M, Wang J, et al. miR‑337‑3p inhibits gastric tumor metastasis by targeting ARHGAP10. Molecular Medicine Reports. 2020;21(2):705-19. [ DOI:10.3892/mmr.2019.10856] 25. Li Q, Huang Q, Cheng S, Wu S, Sang H, Hou J. Circ_ZNF124 promotes non-small cell lung cancer progression by abolishing miR-337-3p mediated downregulation of JAK2/STAT3 signaling pathway. Cancer Cell International. 2019;19(1):291. [ DOI:10.1186/s12935-019-1011-y] [ PMID] [ ] 26. Cao X-M. Role of miR-337-3p and its target Rap1A in modulating proliferation, invasion, migration and apoptosis of cervical cancer cells. Cancer Biomarkers. 2019;24(3):257-67. [ DOI:10.3233/CBM-181225] [ PMID] 27. Eskiocak U, İşeri OD, Kars MD, Biçer A, Gunduz U. Effect of Doxorubicin on Telomerase Activity and Apoptotic Gene Expression in Doxorubicin-Resistant and -Sensitive MCF-7 Cells. Chemotherapy. 2008;54(3):209-16. [ DOI:10.1159/000140464] [ PMID] 28. Staedler D, Idrizi E, Kenzaoui BH, Juillerat-Jeanneret L. Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemotherapy and Pharmacology. 2011;68(5):1161-72. [ DOI:10.1007/s00280-011-1596-x] [ PMID] 29. Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, Kalyanaraman B. Activation of nuclear factor-κB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochemical Journal. 2002;367(3):729-40.
https://doi.org/10.1042/bj20020752 [ DOI:10.1042/BJ20040852] [ PMID] [ ] 30. Tsang W, Chau SP, Kong S, Fung K, Kwok T. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life sciences. 2003;73(16):2047-58. [ DOI:10.1016/S0024-3205(03)00566-6] [ PMID] 31. Ho WC, Dickson KM, Barker PA. Nuclear Factor-κB Induced by Doxorubicin Is Deficient in Phosphorylation and Acetylation and Represses Nuclear Factor-κB-Dependent Transcription in Cancer Cells. Cancer Research. 2005;65(10):4273-81. [ DOI:10.1158/0008-5472.CAN-04-3494] [ PMID] 32. Medeiros MCd, Frasnelli SCT, Bastos AdS, Orrico SRP, Rossa Junior C. Modulation of cell proliferation, survival and gene expression by RAGE and TLR signaling in cells of the innate and adaptive immune response: role of p38 MAPK and NF-KB. Journal of Applied Oral Science. 2014;22:185-93. [ DOI:10.1590/1678-775720130593] [ PMID] [ ] 33. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows archiv. 2005;446:475-82. [ DOI:10.1007/s00428-005-1264-9] [ PMID] 34. Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E, Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Letters. 2007;258(2):181-8. [ DOI:10.1016/j.canlet.2007.08.019] [ PMID] 35. Rebbaa A, Chou PM, Mirkin BL. Factors secreted by human neuroblastoma mediate doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Molecular medicine. 2001;7(6):393-400. [ DOI:10.1007/BF03402185] [ PMID] [ ] 36. Maryam A, Mehmood T, Zhang H, Li Y, Khan M, Ma T. Alantolactone induces apoptosis, promotes STAT3 glutathionylation and enhances chemosensitivity of A549 lung adenocarcinoma cells to doxorubicin via oxidative stress. Scientific reports. 2017;7(1):1-18. [ DOI:10.1038/s41598-017-06535-y] [ PMID] [ ] 37. Shen Q, Yao Q, Sun J, Feng L, Lu H, Ma Y, et al. Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin. FEBS Letters. 2014;588(1):184-91. [ DOI:10.1016/j.febslet.2013.11.034] [ PMID] 38. Ismail IH, Andrin C, McDonald D, Hendzel MJ. BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. Journal of Cell Biology. 2010;191(1):45-60. [ DOI:10.1083/jcb.201003034] [ PMID] [ ] 39. Patel N, Garikapati KR, Pandita RK, Singh DK, Pandita TK, Bhadra U, et al. miR-15a/miR-16 down-regulates BMI1, impacting Ub-H2A mediated DNA repair and breast cancer cell sensitivity to doxorubicin. Scientific Reports. 2017;7(1):4263.
https://doi.org/10.1038/s41598-017-12314-6 [ DOI:10.1038/s41598-017-02800-2] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Tarighi S, Montazeri M, Rohollah F. New Perspective on the Action Mechanism of Doxorubicin in Breast Cancer- Overexpressions of miR-874-3p and miR-337-3p and Downregulation of STAT3 Gene. jhgg 2023; 7 (1) URL: http://humangeneticsgenomics.ir/article-1-96-en.html
|
